Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hexobendine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A known ✓ | P35498 | 2/20 | 0.97 |
| ▸ | SCN2A known ✓ | Q99250 | 2/20 | 0.97 |
| ▸ | SCN3A known ✓ | Q9NY46 | 2/20 | 0.97 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.56 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.56 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.56 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.56 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.56 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.56 |
| ▸ | GHSR known ✓ | Q92847 | 1/20 | 0.56 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.56 |
| ▸ | ABCB1 | P08183 | 10/20 | 0.68 |
| ▸ | ABCG2 | Q9UNQ0 | 10/20 | 0.68 |
| ▸ | ABCC1 | P33527 | 9/20 | 0.68 |
| ▸ | MEN1 | O00255 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.64 |
| ▸ | THPO | P40225 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hexobendine SCHEMBL10402178 | 1.00 | SCN1A (0.97) | SCN1ASCN2ASCN3AABCB1ABCG2 | |
| Hexobendine SCHEMBL2459088 | 1.00 | SCN1A (0.97) | SCN1ASCN2ASCN3AABCB1ABCG2 | |
| Hexobendine SCHEMBL125629 | 0.99 | SCN1A (1.00) | SCN1ASCN2ASCN3AABCB1ABCG2 | |
| SCHEMBL2459622 | 0.89 | SCN1A (0.82) | SCN1ASCN2ASCN3AABCB1ABCG2 | |
| SCHEMBL2459994 | 0.86 | ABCB1 (0.92) | SCN1ASCN2ASCN3AABCB1ABCG2 | |
| SCHEMBL2459996 | 0.86 | ABCB1 (0.92) | SCN1ASCN2ASCN3AABCB1ABCG2 | |
| SCHEMBL25981898 | 0.85 | SCN1A (0.74) | SCN1ASCN2ASCN3AABCB1ABCG2 | |
| Hydrochloric Acid SCHEMBL7883012 | 0.85 | MEN1 (0.77) | SCN1ASCN2ASCN3AABCB1ABCG2 | |
| Dilazep SCHEMBL11130839 | 0.82 | SLC29A1 (0.77) | SCN1ASCN2ASCN3AABCB1ABCG2 | |
| SCHEMBL11219537 | 0.81 | SCN1A (0.69) | SCN1ASCN2ASCN3AABCB1ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250109145-A1 | ORGANIC ELECTROLUMINESCENT DEVICE, AND COMPOUND FOR THE SAME | HODOGAYA CHEMICAL CO., LTD. (JP) | 2025-04-03 | — | — | US | claimed |
| EP-4389753-A1 | ORGANIC ELECTROLUMINESCENT ELEMENT AND COMPOUND FOR SAME | Hodogaya Chemical Co., Ltd. (JP) | 2024-06-26 | — | — | EP | claimed |
| CN-114894846-B | CFRP current-assisted riveting joint connection performance analysis method | 南京航空航天大学 | 2024-04-12 | — | — | CN | claimed |
| US-20230257524-A1 | HIGH MELT TEMPERATURE SOLUBLE SEMI-CRYSTALLINE POLYAMIDES | SOLVAY SPECIALTY POLYMERS USA, LLC (US) | 2023-08-17 | — | — | US | claimed |
| EP-4172238-A1 | HIGH MELT TEMPERATURE SOLUBLE SEMI-CRYSTALLINE POLYAMIDES | Solvay Specialty Polymers USA, LLC. (US) | 2023-05-03 | — | — | EP | claimed |
| CN-115856561-A | Fault diagnosis method and system for rotating rectifier of electric excitation generator | 南京师范大学 | 2023-03-28 | — | — | CN | claimed |
| CN-115087687-A | Polyamide powder and corresponding production method | 阿科玛法国公司 | 2022-09-20 | — | — | CN | claimed |
| CN-114894846-A | CFRP current-assisted riveting joint connection performance analysis method | 南京航空航天大学 | 2022-08-12 | — | — | CN | claimed |
| WO-2025061749-A1 | FLAME-RETARDANT ADHESIVE COMPOSITION | TESA SE (DE) | 2025-03-27 | — | — | WO | disclosed |
| US-12227635-B2 | Stabilizer compositions and methods for using same for protecting polymeric organic materials from UV light and thermal degradation | CYTEC INDUSTRIES INC. (US) | 2025-02-18 | — | — | US | disclosed |
| US-20250026739-A1 | COMPOUNDS AND RADIOLIGANDS FOR TARGETING NEUROTENSIN RECEPTOR AND USES THEREOF | FULL-LIFE TECHNOLOGIES HK LIMITED (CN) | 2025-01-23 | — | — | US | disclosed |
| EP-4479040-A1 | COMPOUNDS AND RADIOLIGANDS FOR TARGETING NEUROTENSIN RECEPTOR AND USES THEREOF | Full-Life Technologies HK Limited (HK) | 2024-12-25 | — | — | EP | disclosed |
| US-12145926-B2 | Compounds and radioligands for targeting neurotensin receptor and uses thereof | FULL-LIFE TECHNOLOGIES HK LIMITED (CN) | 2024-11-19 | — | — | US | disclosed |
| US-20240287046-A1 | COMPOUNDS AND RADIOLIGANDS FOR TARGETING NEUROTENSIN RECEPTOR AND USES THEREOF | FULL-LIFE TECHNOLOGIES HK LIMITED (CN) | 2024-08-29 | — | — | US | disclosed |
| US-20140128399-A1 | METHODS AND COMPOSITIONS FOR TREATING URINARY TRACT INFECTIONS USING AGENTS THAT MIMIC OR ELEVATE CYCLIC AMP | DUKE UNIVERSITY (US) | 2014-05-08 | — | — | US | disclosed |
| US-8092819-B2 | Implantable medical device coated with a bioactive agent | Cook Medical Technologies LLC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20110171195-A1 | METHODS AND COMPOSITIONS FOR TREATING URINARY TRACT INFECTIONS USING AGENTS THAT MIMIC OR ELEVATE CYCLIC AMP | DUKE UNIVERSITY (US) | 2011-07-14 | — | — | US | disclosed |
| WO-2008157205-A2 | METHODS AND COMPOSITIONS FOR TREATING URINARY TRACT INFECTIONS USING AGENTS THAT MIMIC OR ELEVATE CYCLIC AMP | DUKE UNIVERSITY (US) | 2008-12-24 | — | — | WO | disclosed |
| US-20070207184-A1 | Implantable medical device coated with a bioactive agent | MED INSTITUTE, INC (US) | 2007-09-06 | — | — | US | disclosed |
| US-4902516-A | WITH COATING OF POLY-3-HYDROXYBUTYROLACTONE; DRUG DELIVERY | CHEMIE HOLDING AKTIENGESELLSCHAFT (AT) | 1990-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026739-A1 | COMPOUNDS AND RADIOLIGANDS FOR TARGETING NEUROTENSIN RECEPTOR AND USES THEREOF | NTSR1, NTSR2, NPSR1 | SCN1A 1246/4885SCN2A 1298/4885SCN3A 802/4885 |
| US-20240287046-A1 | COMPOUNDS AND RADIOLIGANDS FOR TARGETING NEUROTENSIN RECEPTOR AND USES THEREOF | NTSR1, NTSR2, NPSR1 | SCN1A 1210/4885SCN2A 1394/4885SCN3A 799/4885 |
| US-20110171195-A1 | METHODS AND COMPOSITIONS FOR TREATING URINARY TRACT INFECTIONS USING AGENTS THAT MIMIC OR ELEVATE CYCLIC AMP | PDE7A, PDE8A, PDE8B | SCN1A 4840/4885SCN2A 4841/4885SCN3A 4621/4885 |
| US-12145926-B2 | Compounds and radioligands for targeting neurotensin receptor and uses thereof | NTSR1, NTSR2, NPSR1 | SCN1A 1210/4885SCN2A 1394/4885SCN3A 799/4885 |
| US-20250109145-A1 | ORGANIC ELECTROLUMINESCENT DEVICE, AND COMPOUND FOR THE SAME | TYR, AZI2, AOC1 | SCN1A 4073/4885SCN2A 4086/4885SCN3A 3863/4885 |
| US-20140128399-A1 | METHODS AND COMPOSITIONS FOR TREATING URINARY TRACT INFECTIONS USING AGENTS THAT MIMIC OR ELEVATE CYCLIC AMP | PDE7A, PDE8A, PDE8B | SCN1A 4840/4885SCN2A 4841/4885SCN3A 4621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.